In April slide deck, they said DoR and PFS data that will be presented are preliminary. One thing that I found interesting is that for EGFR TKIs used in lung cancer, the mDoR is almost always shorter than the mPFS, or at most, very close to it. This is the opposite of many other cancer treatments (like immunotherapy), where mDoR is often much longer than mPFS.
Market Data 
Markets 
